

Michael Goggins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11069427/publications.pdf>

Version: 2024-02-01

227
papers

40,839
citations

2203

99
h-index

2439

197
g-index

234
all docs

234
docs citations

234
times ranked

36732
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2267-2275.e2.	2.4	8
2	Endoplasmic stressâ€”inducing variants in <scp><i>CPB1</i></scp> and <scp><i>CPA1</i></scp> and risk of pancreatic cancer: A caseâ€”control study and metaâ€”analysis. <i>International Journal of Cancer</i> , 2022, 150, 1123-1133.	2.3	11
3	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. <i>Journal of Clinical Oncology</i> , 2022, 40, 3257-3266.	0.8	69
4	Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 938-941.	0.5	1
5	COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. <i>Pancreatology</i> , 2021, 21, 1048-1051.	0.5	8
6	Inherited Pancreatic Cancer Syndromes and High-Risk Screening. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 773-786.	0.6	16
7	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?â€”Letter. <i>Cancer Prevention Research</i> , 2021, 14, 973-974.	0.7	3
8	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1161-1169.e5.	2.4	31
9	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1003-1012.	3.0	59
10	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020, 69, 7-17.	6.1	357
11	Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. <i>Cancer Letters</i> , 2020, 493, 245-253.	3.2	18
12	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. <i>Journal of Pathology</i> , 2020, 252, 252-262.	2.1	30
13	Genome-Wide Geneâ€”Diabetes and Geneâ€”Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1784-1791.	1.1	5
14	Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1162-1169.	3.0	114
15	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 748-756.	1.2	11
16	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 380-391.	2.3	314
17	Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. <i>Modern Pathology</i> , 2019, 32, 1806-1813.	2.9	21
18	Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 658-676.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2104-2111.	0.7	64
20	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2019, 37, 153-164.	0.8	135
21	Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. <i>Gastroenterology</i> , 2019, 156, 1905-1913.	0.6	47
22	Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. <i>Journal of Clinical Oncology</i> , 2019, 37, 1070-1080.	0.8	65
23	Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 477-483.	0.9	8
24	Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. <i>Modern Pathology</i> , 2019, 32, 659-665.	2.9	20
25	Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 5592-5604.	0.8	6
26	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. <i>ELife</i> , 2019, 8, .	2.8	103
27	Mutations in the pancreatic secretory enzymes <i>CPA1</i> and <i>CPB1</i> are associated with pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4767-4772.	3.3	65
28	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	5.8	188
29	BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2018, 226, 630-637e1.	0.2	62
30	Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. <i>Clinical Cancer Research</i> , 2018, 24, 2963-2974.	3.2	55
31	Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. <i>American Journal of Pathology</i> , 2018, 188, 1723-1733.	1.9	32
32	Diagnostic Biomarkers. , 2018, , 659-680.		4
33	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 46-55.	1.2	16
34	The Effect of Pancreatic Juice Collection Time on the Detection of KRAS Mutations. <i>Pancreas</i> , 2018, 47, 35-39.	0.5	11
35	Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. <i>Gastroenterology</i> , 2018, 155, 740-751.e2.	0.6	288
36	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 145-152.	2.2	34

#	ARTICLE	IF	CITATIONS
37	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. <i>Gut</i> , 2017, 66, 1677-1687.	6.1	134
38	Using an endoscopic distal cap to collect pancreatic fluid from the ampulla (with video). <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1152-1156.e2.	0.5	10
39	Diagnostic Biomarkers. , 2017, , 1-22.		0
40	Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2379-2386.	0.7	14
41	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. <i>Cell Cycle</i> , 2017, 16, 991-998.	1.3	24
42	Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. <i>Annals of Surgery</i> , 2017, 266, 133-141.	2.1	106
43	Editorial: Circulating Biomarkers to Identify Patients With Resectable Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	3
44	Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. <i>Cancer Cell</i> , 2017, 32, 824-839.e8.	7.7	97
45	Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2681-2690.	3.2	91
46	IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. <i>Oncotarget</i> , 2017, 8, 83370-83383.	0.8	14
47	Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3382-3390.	0.8	316
48	Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 50824-50831.	0.8	11
49	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44073-44081.	0.8	63
50	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , 2016, 7, 66328-66343.	0.8	88
51	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. <i>Cancer Research</i> , 2016, 76, 3351-3363.	0.4	29
52	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 166-175.	7.7	282
53	Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. <i>Cancer Science</i> , 2016, 107, 569-575.	1.7	106
54	Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2016, 11, e0164195.	1.1	15

#	ARTICLE	IF	CITATIONS
55	Overexpression of <i>ankyrin1</i> promotes pancreatic cancer cell growth. <i>Oncotarget</i> , 2016, 7, 34977-34987.	0.8	18
56	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1730-1741.	2.1	626
57	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
58	Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk. <i>PLoS ONE</i> , 2015, 10, e0117574.	1.1	29
59	A histomorphologic comparison of familial and sporadic pancreatic cancers. <i>Pancreatology</i> , 2015, 15, 387-391.	0.5	32
60	Pathological and Molecular Evaluation of Pancreatic Neoplasms. <i>Seminars in Oncology</i> , 2015, 42, 28-39.	0.8	64
61	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	0.6	376
62	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015, 47, 911-916.	9.4	224
63	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 963-969.e4.	2.4	74
64	Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. <i>European Journal of Radiology</i> , 2015, 84, 575-580.	1.2	19
65	Classifying pancreatic cancer using gene expression profiling. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 613-614.	8.2	8
66	Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. <i>Gut</i> , 2015, 64, 1783-1789.	6.1	157
67	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
68	Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e62.	1.3	28
69	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	1.4	90
70	Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. <i>Journal of Pathology</i> , 2014, 233, 217-227.	2.1	308
71	A Systematic Review of Solid-Pseudopapillary Neoplasms. <i>Pancreas</i> , 2014, 43, 331-337.	0.5	276
72	Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis. <i>Clinical Cancer Research</i> , 2014, 20, 1865-1872.	3.2	81

#	ARTICLE	IF	CITATIONS
73	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	9.4	294
74	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. <i>Cancer Research</i> , 2014, 74, 3381-3389.	0.4	207
75	Role of a Multidisciplinary Clinic in the Management of Patients with Pancreatic Cysts: A Single-Center Cohort Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 3668-3674.	0.7	45
76	Liver transplant patients have a similar risk of progression as sporadic patients with branch duct intraductal papillary mucinous neoplasms. <i>Liver Transplantation</i> , 2014, 20, n/a-n/a.	1.3	7
77	Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. <i>Oncotarget</i> , 2014, 5, 2575-2587.	0.8	29
78	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. <i>Gut</i> , 2013, 62, 339-347.	6.1	672
79	Mutant TP53 in Duodenal Samples of Pancreatic Juice From Patients With Pancreatic Cancer or High-Grade Dysplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 719-730.e5.	2.4	154
80	DNA Methylation Analysis in Human Cancer. <i>Methods in Molecular Biology</i> , 2013, 980, 131-156.	0.4	8
81	Epigenetic Alterations in Pancreatic Cancer. , 2013, , 185-207.		1
82	Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. <i>Cancer Causes and Control</i> , 2013, 24, 595-602.	0.8	4
83	PAM4 enzyme immunoassay alone and in combination with CA 19â€9 for the detection of pancreatic adenocarcinoma. <i>Cancer</i> , 2013, 119, 522-528.	2.0	38
84	Serum miR-1290 as a Marker of Pancreatic Cancerâ€™ Response. <i>Clinical Cancer Research</i> , 2013, 19, 5252-5253.	3.2	12
85	Mutant <i>GNAS</i> detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. <i>Gut</i> , 2013, 62, 1024-1033.	6.1	160
86	MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls. <i>Clinical Cancer Research</i> , 2013, 19, 3600-3610.	3.2	279
87	An Absolute Risk Model to Identify Individuals at Elevated Risk for Pancreatic Cancer in the General Population. <i>PLoS ONE</i> , 2013, 8, e72311.	1.1	120
88	<i>ATM</i> Mutations in Patients with Hereditary Pancreatic Cancer. <i>Cancer Discovery</i> , 2012, 2, 41-46.	7.7	442
89	Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Clinical Cancer Research</i> , 2012, 18, 700-712.	3.2	69
90	GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata. <i>Diabetes</i> , 2012, 61, 989-990.	0.3	9

#	ARTICLE	IF	CITATIONS
91	Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4303-4312.	3.2	43
92	Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. <i>Carcinogenesis</i> , 2012, 33, 1384-1390.	1.3	102
93	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. <i>Nature</i> , 2012, 486, 266-270.	13.7	297
94	Vascular Invasion in Infiltrating Ductal Adenocarcinoma of the Pancreas Can Mimic Pancreatic Intraepithelial Neoplasia. <i>American Journal of Surgical Pathology</i> , 2012, 36, 235-241.	2.1	44
95	MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias. <i>Clinical Cancer Research</i> , 2012, 18, 981-992.	3.2	198
96	Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. <i>Human Pathology</i> , 2012, 43, 585-591.	1.1	56
97	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. <i>Gastroenterology</i> , 2012, 142, 730-733.e9.	0.6	568
98	Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. <i>Gastroenterology</i> , 2012, 142, 796-804.	0.6	570
99	Unlike Pancreatic Cancer Cells Pancreatic Cancer Associated Fibroblasts Display Minimal Gene Induction after 5-Aza-2-Deoxycytidine. <i>PLoS ONE</i> , 2012, 7, e43456.	1.1	24
100	Detectable clonal mosaicism and its relationship to aging and cancer. <i>Nature Genetics</i> , 2012, 44, 651-658.	9.4	519
101	Somatic mutations in the chromatin remodeling gene <i>ARID1A</i> occur in several tumor types. <i>Human Mutation</i> , 2012, 33, 100-103.	1.1	263
102	Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 3493-3499.	0.7	62
103	Pancreatic cancer. <i>Lancet</i> , The, 2011, 378, 607-620.	6.3	2,155
104	Risk Factors of Familial Pancreatic Cancer in Japan. <i>Pancreas</i> , 2011, 40, 974-978.	0.5	36
105	Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. <i>Indian Journal of Surgical Oncology</i> , 2011, 2, 9-15.	0.3	2
106	Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. <i>Modern Pathology</i> , 2011, 24, 256-266.	2.9	34
107	Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. <i>Modern Pathology</i> , 2011, 24, 1237-1247.	2.9	90
108	Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 4341-4354.	3.2	154

#	ARTICLE	IF	CITATIONS
109	Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. <i>Science Translational Medicine</i> , 2011, 3, 92ra66.	5.8	703
110	Markers of Pancreatic Cancer: Working Toward Early Detection. <i>Clinical Cancer Research</i> , 2011, 17, 635-637.	3.2	39
111	Molecular Signatures of Pancreatic Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 716-727.	1.2	130
112	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. <i>Nature Genetics</i> , 2010, 42, 224-228.	9.4	539
113	Detection of Early-Stage Pancreatic Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2786-2794.	1.1	45
114	Cyclooxygenase-Deficient Pancreatic Cancer Cells Use Exogenous Sources of Prostaglandins. <i>Molecular Cancer Research</i> , 2010, 8, 821-832.	1.5	27
115	Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 340-351.	3.0	392
116	Pancreatic Cancers Epigenetically Silence <i>SIP1</i> and Hypomethylate and Overexpress <i>miR-200a/200b</i> in Association with Elevated Circulating <i>miR-200a</i> and <i>miR-200b</i> Levels. <i>Cancer Research</i> , 2010, 70, 5226-5237.	0.4	268
117	Overexpression of Smoothed Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer-Associated Fibroblasts. <i>Clinical Cancer Research</i> , 2010, 16, 1781-1789.	3.2	159
118	Pancreatic cancer <i>DNMT1</i> expression and sensitivity to <i>DNMT1</i> inhibitors. <i>Cancer Biology and Therapy</i> , 2010, 9, 321-329.	1.5	54
119	Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling. <i>Cancer Research</i> , 2010, 70, 4460-4469.	0.4	140
120	Surveillance in individuals at high risk of pancreatic cancer: too early to tell?. <i>Gut</i> , 2010, 59, 1005-1005.	6.1	5
121	Update on Familial Pancreatic Cancer. <i>Advances in Surgery</i> , 2010, 44, 293-311.	0.6	224
122	ABO blood group and other genetic variants associated with pancreatic cancer. <i>Genome Medicine</i> , 2010, 2, 39.	3.6	4
123	Diagnostic and Therapeutic Response Markers. , 2010, , 675-701.		7
124	Development of Novel Pancreatic Tumor Biomarkers. , 2010, , 1173-1201.		0
125	Absence of Deleterious Palladin Mutations in Patients with Familial Pancreatic Cancer: Table 1.. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1328-1330.	1.1	39
126	Exomic Sequencing Identifies <i>PALB2</i> as a Pancreatic Cancer Susceptibility Gene. <i>Science</i> , 2009, 324, 217-217.	6.0	713

#	ARTICLE	IF	CITATIONS
127	Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2829-2834.	1.1	65
128	Absence of germline BRCA1 mutations in familial pancreatic cancer patients. <i>Cancer Biology and Therapy</i> , 2009, 8, 131-135.	1.5	50
129	Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. <i>Cancer Research</i> , 2009, 69, 3681-3688.	0.4	126
130	<i>SMAD4</i> Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4674-4679.	3.2	335
131	Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. <i>Clinical Cancer Research</i> , 2009, 15, 7737-7743.	3.2	195
132	Serum Fatty Acid Synthase as a Marker of Pancreatic Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2380-2385.	1.1	81
133	<i>KRAS2</i> Mutations in Human Pancreatic Acinar-Ductal Metaplastic Lesions Are Limited to Those with PanIN: Implications for the Human Pancreatic Cancer Cell of Origin. <i>Molecular Cancer Research</i> , 2009, 7, 230-236.	1.5	98
134	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2009, 41, 986-990.	9.4	597
135	Epigenetics and epigenetic alterations in pancreatic cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2009, 2, 310-26.	0.5	54
136	Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. <i>Modern Pathology</i> , 2008, 21, 1499-1507.	2.9	79
137	CpG island methylation profile of pancreatic intraepithelial neoplasia. <i>Modern Pathology</i> , 2008, 21, 238-244.	2.9	119
138	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. <i>Science</i> , 2008, 321, 1801-1806.	6.0	3,755
139	DNA Methylation Alterations In Endoscopic Retrograde Cholangiopancreatography Brush Samples of Patients With Suspected Pancreaticobiliary Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1270-1278.	2.4	73
140	Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2008, 7, 1146-1156.	1.5	165
141	Pancreatic cancer associated fibroblasts display normal allelotypes. <i>Cancer Biology and Therapy</i> , 2008, 7, 882-888.	1.5	76
142	Allele-specific expression in the germline of patients with familial pancreatic cancer: An unbiased approach to cancer gene discovery. <i>Cancer Biology and Therapy</i> , 2008, 7, 135-144.	1.5	42
143	Genetic and Epigenetic Alterations of Familial Pancreatic Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3536-3542.	1.1	79
144	New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8. <i>American Journal of Surgical Pathology</i> , 2008, 32, 188-196.	2.1	121

#	ARTICLE	IF	CITATIONS
145	Pancreatic Cancer Genomics, Epigenomics, and Proteomics. , 2008, , 229-252.		0
146	Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. International Journal of Clinical and Experimental Pathology, 2008, 1, 343-51.	0.5	18
147	Update on pancreatic intraepithelial neoplasia. International Journal of Clinical and Experimental Pathology, 2008, 1, 306-16.	0.5	159
148	Emerging molecular biology of pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S10-5.	0.8	14
149	The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 342-346.	1.1	255
150	Copy-number variants in patients with a strong family history of pancreatic cancer. Cancer Biology and Therapy, 2007, 6, 1592-1599.	1.5	36
151	Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biology and Therapy, 2007, 6, 324-328.	1.5	50
152	Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biology and Therapy, 2007, 6, 1569-1575.	1.5	63
153	Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2007, 25, 319-325.	0.8	372
154	Genome-Wide Allelotypes of Familial Pancreatic Adenocarcinomas and Familial and Sporadic Intraductal Papillary Mucinous Neoplasms. Clinical Cancer Research, 2007, 13, 6019-6025.	3.2	52
155	Familial pancreatic cancer: from genes to improved patient care. Expert Review of Gastroenterology and Hepatology, 2007, 1, 81-88.	1.4	16
156	Precursors to Pancreatic Cancer. Gastroenterology Clinics of North America, 2007, 36, 831-849.	1.0	174
157	Identifying Molecular Markers for the Early Detection of Pancreatic Neoplasia. Seminars in Oncology, 2007, 34, 303-310.	0.8	89
158	Clinical importance of precursor lesions in the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 2007, 14, 255-263.	2.0	64
159	Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clinical Gastroenterology and Hepatology, 2006, 4, 766-781.	2.4	493
160	Differential and Epigenetic Gene Expression Profiling Identifies Frequent Disruption of the RELN Pathway in Pancreatic Cancers. Gastroenterology, 2006, 130, 548-565.	0.6	139
161	Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 280-285.	2.0	44
162	The role of epigenetic alterations in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 286-295.	2.0	83

#	ARTICLE	IF	CITATIONS
163	Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. <i>Cancer Detection and Prevention</i> , 2006, 30, 180-187.	2.1	31
164	Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2006, 107, 251-257.	2.0	43
165	Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: Heteroduplex analysis of limiting dilution PCRs. <i>Cancer Biology and Therapy</i> , 2006, 5, 1392-1399.	1.5	19
166	Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. <i>Cancer Biology and Therapy</i> , 2006, 5, 1383-1389.	1.5	48
167	Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9. <i>Clinical Cancer Research</i> , 2006, 12, 442-446.	3.2	197
168	DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease. <i>Cancer Research</i> , 2006, 66, 1208-1217.	0.4	207
169	Pancreatic Cancer Genetic Epidemiology Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 704-710.	1.1	133
170	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1067-76.	2.1	261
171	Identification of Differentially Expressed Proteins in Pancreatic Cancer Using a Global Proteomic Approach. , 2005, 103, 189-198.		11
172	Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2005, 24, 850-858.	2.6	144
173	Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. <i>Oncogene</i> , 2005, 24, 3652-3656.	2.6	68
174	Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2005, 18, 779-787.	2.9	66
175	Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. <i>Modern Pathology</i> , 2005, 18, 959-963.	2.9	101
176	Gene Expression Profiles in Pancreatic Intraepithelial Neoplasia Reflect the Effects of Hedgehog Signaling on Pancreatic Ductal Epithelial Cells. <i>Cancer Research</i> , 2005, 65, 1619-1626.	0.4	223
177	Increased Cyclooxygenase-2 Expression in Duodenal Compared with Colonic Tissues in Familial Adenomatous Polyposis and Relationship to the 765G > C COX-2 Polymorphism. <i>Clinical Cancer Research</i> , 2005, 11, 4090-4096.	3.2	58
178	The Chemokine Receptor CXCR4 is Regulated by DNA Methylation in Pancreatic Cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 77-83.	1.5	100
179	Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling. <i>Clinical Cancer Research</i> , 2005, 11, 4681-4688.	3.2	108
180	Aberrant methylation of the human hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. <i>Cancer Biology and Therapy</i> , 2005, 4, 728-733.	1.5	83

#	ARTICLE	IF	CITATIONS
181	Expression and prognostic significance of 14-3-3 sigma and ERM family protein expression in periampullary neoplasms. <i>Cancer Biology and Therapy</i> , 2005, 4, 596-601.	1.5	24
182	Molecular Markers of Early Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4524-4531.	0.8	212
183	Pancreaticobiliary Cancers With Deficient Methylenetetrahydrofolate Reductase Genotypes. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 752-760.	2.4	40
184	The Genetics of <i>FANCC</i> and <i>FANCG</i> in Familial Pancreatic Cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 167-169.	1.5	78
185	The Human MitoChip: A High-Throughput Sequencing Microarray for Mitochondrial Mutation Detection. <i>Genome Research</i> , 2004, 14, 812-819.	2.4	218
186	Gene Expression Profiling of Tumor-Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts. <i>Cancer Research</i> , 2004, 64, 6950-6956.	0.4	145
187	Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry. <i>Clinical Cancer Research</i> , 2004, 10, 860-868.	3.2	273
188	Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds. <i>Cancer Research</i> , 2004, 64, 2634-2638.	0.4	595
189	Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients. <i>Journal of Experimental Medicine</i> , 2004, 200, 297-306.	4.2	314
190	Gene expression profiling identifies markers of ampullary adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2004, 3, 651-656.	1.5	35
191	Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers. <i>Clinical Cancer Research</i> , 2004, 10, 2386-2392.	3.2	250
192	Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. <i>Cancer Biology and Therapy</i> , 2004, 3, 1254-1261.	1.5	73
193	Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. <i>Oncogene</i> , 2004, 23, 1531-1538.	2.6	154
194	Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. <i>Oncogene</i> , 2004, 23, 9042-9051.	2.6	103
195	Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 606-621.	2.4	431
196	Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>American Journal of Pathology</i> , 2004, 164, 903-914.	1.9	190
197	An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms. <i>American Journal of Surgical Pathology</i> , 2004, 28, 977-987.	2.1	964
198	Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. <i>Cancer Biology and Therapy</i> , 2004, 3, 1081-1089.	1.5	52

#	ARTICLE	IF	CITATIONS
199	SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. <i>Oncogene</i> , 2003, 22, 5021-5030.	2.6	263
200	Loss of Stk11/Lkb1 Expression in Pancreatic and Biliary Neoplasms. <i>Modern Pathology</i> , 2003, 16, 686-691.	2.9	104
201	Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays. <i>American Journal of Pathology</i> , 2003, 162, 1151-1162.	1.9	450
202	Effects of 5-Aza-2'-deoxycytidine on Matrix Metalloproteinase Expression and Pancreatic Cancer Cell Invasiveness. <i>Journal of the National Cancer Institute</i> , 2003, 95, 327-330.	3.0	106
203	Diagnosing Pancreatic Cancer Using Methylation Specific PCR Analysis. <i>Cancer Biology and Therapy</i> , 2003, 2, 79-84.	1.5	107
204	p16 Inactivation in Pancreatic Intraepithelial Neoplasias (PanINs) Arising in Patients With Chronic Pancreatitis. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1495-1501.	2.1	104
205	Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. <i>Cancer Research</i> , 2003, 63, 3735-42.	0.4	267
206	Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. <i>Cancer Research</i> , 2003, 63, 4158-66.	0.4	238
207	Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. <i>Cancer Research</i> , 2003, 63, 8614-22.	0.4	336
208	Immunohistochemical Validation of a Novel Epithelial and a Novel Stromal Marker of Pancreatic Ductal Adenocarcinoma Identified by Global Expression Microarrays. <i>American Journal of Clinical Pathology</i> , 2002, 118, 52-59.	0.4	124
209	Aberrant Methylation of the 5' CpG Island of TSLC1 Is Common in Pancreatic Ductal Adenocarcinoma and Is First Manifest in High-Grade PanINs. <i>Cancer Biology and Therapy</i> , 2002, 1, 293-296.	1.5	112
210	Aberrant Methylation of Preproenkephalin and p16 Genes in Pancreatic Intraepithelial Neoplasia and Pancreatic Ductal Adenocarcinoma. <i>American Journal of Pathology</i> , 2002, 160, 1573-1581.	1.9	205
211	Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology. <i>American Journal of Pathology</i> , 2002, 160, 1239-1249.	1.9	271
212	Overexpression of S100A4 in Pancreatic Ductal Adenocarcinomas Is Associated with Poor Differentiation and DNA Hypomethylation. <i>American Journal of Pathology</i> , 2002, 160, 45-50.	1.9	203
213	Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. <i>Gastroenterology</i> , 2002, 123, 365-372.	0.6	124
214	Early detection of pancreatic carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2002, 16, 37-52.	0.9	130
215	Phenotypic variation in eight extendedCDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families. <i>Cancer</i> , 2002, 94, 84-96.	2.0	221
216	Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. <i>Oncogene</i> , 2002, 21, 2114-2117.	2.6	49

#	ARTICLE	IF	CITATIONS
217	Pancreatic cancer. <i>Current Problems in Cancer</i> , 2002, 26, 176-275.	1.0	268
218	Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. <i>Cancer Research</i> , 2002, 62, 1868-75.	0.4	233
219	STK11/LKB1 Peutz-Jeghers Gene Inactivation in Intraductal Papillary-Mucinous Neoplasms of the Pancreas. <i>American Journal of Pathology</i> , 2001, 159, 2017-2022.	1.9	251
220	Nuclear Localization of Dpc4 (Madh4, Smad4) in Colorectal Carcinomas and Relation to Mismatch Repair/Transforming Growth Factor- β 2 Receptor Defects. <i>American Journal of Pathology</i> , 2001, 158, 537-542.	1.9	25
221	Can we screen high-risk individuals to detect early pancreatic carcinoma?. <i>Journal of Surgical Oncology</i> , 2000, 74, 243-248.	0.8	62
222	Genetic, Immunohistochemical, and Clinical Features of Medullary Carcinoma of the Pancreas. <i>American Journal of Pathology</i> , 2000, 156, 1641-1651.	1.9	263
223	BRCA2 Is Inactivated Late in the Development of Pancreatic Intraepithelial Neoplasia. <i>American Journal of Pathology</i> , 2000, 156, 1767-1771.	1.9	192
224	Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. <i>Gastroenterology</i> , 2000, 119, 1756-1760.	0.6	30
225	Germline and Somatic Mutations of the STK11/LKB1 Peutz-Jeghers Gene in Pancreatic and Biliary Cancers. <i>American Journal of Pathology</i> , 1999, 154, 1835-1840.	1.9	380
226	Molecular genetics and related developments in pancreatic cancer. <i>Current Opinion in Gastroenterology</i> , 1999, 15, 404.	1.0	20
227	Tumor-Suppressor genes in pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998, 5, 383-391.	2.0	40